Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
Masoabi Sefojane, Geographic Expansion Lead, Africa and Asia Pacific at MicroHealth , shared a post on LinkedIn:
”The World Federation of Haemophilia identifies 37% of people with haemophilia globally.
In low-income countries? 11%.
In Africa? An estimated 88% remain undiagnosed.
Let me be direct: these numbers represent invisibility by design.
Not because diagnosis is impossible.
But because the systems to find people were built for certain geographies and certain people.
When my brother was 6 years old in Phuthaditjhaba, South Africa, He didn’t exist in any global haemophilia dataset.
He was bleeding, my family was desperate, but he was invisible. No screening protocol would find him.
No registry would record him. No system knew he existed. This could have been my story if it wasn’t for my brothers.
Ask any bleeding disorder patient in the global south and you will hear similar stories and a pattern will also emerge.
Meanwhile, a child born with the same severe haemophilia A in Amsterdam? Known by age 1. Registered. Part of the data that shapes global priorities.
Same disease. Different visibility.
Here’s what the data shows: Africa, with 18% of the world’s population, represents less than 3% of identified haemophilia patients globally.
That’s not because haemophilia is rare in Africa. It’s because the systems designed to find haemophilia were never designed to reach Africa.
The invisibility isn’t accidental. It’s structural.
When a patient is invisible, they don’t exist in clinical trials. They’re not counted in epidemiology.
They don’t influence treatment guidelines. Their outcomes don’t matter because nobody’s measuring them.
The question we need to ask: Are we actually looking for these patients?
Or have we built systems that only find the ones in certain places?
Because that’s the real diagnosis gap.”
Stay updated with Hemostasis Today.
-
May 6, 2026, 12:36Alan Nurden: CRISPR-Mediated Megakaryocyte Modeling in Glanzmann Thrombasthenia
-
May 6, 2026, 12:12Mona Ranade: Insights from a Medeloop Analytics Study Evaluate Catheter-Directed Therapy in Pulmonary Embolism
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?
-
May 6, 2026, 02:47Karen Rollinson: Connecting with so Many Families and Advocates at HFA 2026